Trademark Overview
On Friday, February 11, 2022, a trademark application was filed for DECREVO with the United States Patent and Trademark Office. The USPTO has given the DECREVO trademark a serial number of 97263821. The federal status of this trademark filing is ABANDONED - EXPRESS as of Thursday, June 30, 2022. This trademark is owned by Glaxo Group Limited. The DECREVO trademark is filed in the Pharmaceutical Products category with the following description:
(Based on Intent to Use) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders(Based on 44(d) Priority Application) Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gas...
